$TSOI Therapeutic Solutions International adds Nan
Post# of 88870
(Total Views: 103)
Posted On: 07/15/2019 10:38:42 AM
$TSOI Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer
OCEANSIDE, CA -- July 15, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the addition of nano particle cannabidiol to NanoMyros in the form of our proprietary product Nano Cannabidiol.
Cannabidiol (also known as CBD) is a phytocannabinoid derived from the cannabis species, is devoid of psychoactive activity, but has analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms.
The addition of "Nano Cannabidiol" to NanoMyros is to inhibit microvesicles and exosomes from being released by other cells in communication intracellularly through the transfer of proteins. Microvesicle and exosome release has been associated with multiple pathologies, including many cancers, which increases drug resistance and the transfer of other pro-oncogenic factors.
"This final piece of this unique synergistic blend of pterostilbene, glucoraphanin, myrosinase, and now cannabidiol is not available by any other manufacturer that we are aware of and is built entirely on our nano products NanoStilbene and Nano Cannabidiol," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We will offer the NanoMyros with and without Nano Cannabidiol so as not to restrict anyone from the benefits of NanoPSA and NanoMyros as stand-alone nutraceuticals."
"Preliminary data from our collaborators indicates that this combination is effective at decreasing both production of pathological exosomes, as well as the responsiveness of target cells to pathological exosomes," said Thomas Ichim, Ph.D., Board Member of TSOI. "Specifically, we have demonstrated that subsequent to treatment of cancer cells using the combination product, there was both a decrease in the production of Fas ligand bearing exosomes, which are known to kill immune cells, as well as an increased resistance of immune cells to killing by Fas ligand bearing exosomes produced by cancer."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downreg
OCEANSIDE, CA -- July 15, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the addition of nano particle cannabidiol to NanoMyros in the form of our proprietary product Nano Cannabidiol.
Cannabidiol (also known as CBD) is a phytocannabinoid derived from the cannabis species, is devoid of psychoactive activity, but has analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms.
The addition of "Nano Cannabidiol" to NanoMyros is to inhibit microvesicles and exosomes from being released by other cells in communication intracellularly through the transfer of proteins. Microvesicle and exosome release has been associated with multiple pathologies, including many cancers, which increases drug resistance and the transfer of other pro-oncogenic factors.
"This final piece of this unique synergistic blend of pterostilbene, glucoraphanin, myrosinase, and now cannabidiol is not available by any other manufacturer that we are aware of and is built entirely on our nano products NanoStilbene and Nano Cannabidiol," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We will offer the NanoMyros with and without Nano Cannabidiol so as not to restrict anyone from the benefits of NanoPSA and NanoMyros as stand-alone nutraceuticals."
"Preliminary data from our collaborators indicates that this combination is effective at decreasing both production of pathological exosomes, as well as the responsiveness of target cells to pathological exosomes," said Thomas Ichim, Ph.D., Board Member of TSOI. "Specifically, we have demonstrated that subsequent to treatment of cancer cells using the combination product, there was both a decrease in the production of Fas ligand bearing exosomes, which are known to kill immune cells, as well as an increased resistance of immune cells to killing by Fas ligand bearing exosomes produced by cancer."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downreg
(0)
(0)Scroll down for more posts ▼